Every S-3 that Microbot Med Inc (MBOT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A S-3 covers the shelf registration that lets an established company sell over time, so if you follow MBOT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MBOT filings page.
Microbot Medical Inc. filed Amendment No. 1 to its Form S-3 registration statement. The amendment adds Rule 473(b) language for automatic effectiveness 20 days following filing and updates a cross-reference in the exhibit index. It does not modify any provision of the prospectus, and a preliminary prospectus has been omitted.
The filing states effectiveness will occur in accordance with Section 8(a) of the Securities Act. Listed issuance and distribution expenses total $25,000.00, including an SEC registration fee of $404.02, with legal, accounting, and miscellaneous costs itemized.
Microbot Medical Inc. (MBOT) filed Amendment No. 1 to its shelf registration statement, stating it is being made solely to add Rule 473(b) language for automatic effectiveness 20 days after filing and to update a cross-reference in the Exhibit Index. The amendment does not modify any prospectus, and a preliminary prospectus has been omitted.
The filing notes the registration will become effective in accordance with Section 8(a), and the company may amend to delay or change effectiveness if the SEC resumes full operation beforehand. Disclosed offering-related expenses total $27,000.00, including an SEC registration fee of $6,592.60, legal fees of $5,000.00, accounting fees of $12,000.00, and miscellaneous expenses of $3,407.40.
Microbot Medical Inc. (MBOT) filed a preliminary S-3 prospectus registering up to 14,688,572 shares of common stock for resale by selling stockholders. The shares may be issued upon exercise of outstanding preferred investment options, including 13,989,115 Series J options at an exercise price of $4.50 per share. This prospectus does not cover the issuance of the underlying shares to the holders and the company is not selling any shares.
Microbot will not receive proceeds from stockholder resales. If all 14,688,572 options are exercised for cash, the company may receive up to approximately $64.8 million in gross proceeds; certain options permit cashless exercise. Shares outstanding were 67,158,044 as of October 10, 2025. Listed methods permit brokerage transactions, block trades, privately negotiated sales, and short sales after the registration statement is declared effective.
MBOT trades on Nasdaq; the last reported closing price on October 10, 2025 was $2.92.
Microbot Medical Inc. (MBOT) filed a preliminary S-3 registering up to 900,153 shares of common stock for resale by selling stockholders. The shares may be issued upon exercise of outstanding preferred investment options held by those stockholders. The company is not selling shares in this offering and will not receive proceeds from any resales.
Microbot may receive up to approximately $2.1 million in gross proceeds only if all registered options are exercised for cash; some options allow cashless exercise. The plan of distribution permits multiple methods, including short sales after the registration statement is declared effective. Examples include Noam Rubenstein 283,548 and Michael Vasinkevich 577,223 from the selling stockholder table. Shares outstanding were 67,158,044 as of October 10, 2025. MBOT last closed at $2.92 on October 10, 2025.